

Impact of tenofovir on hepatitis delta virus replication in the Swiss HIV Cohort Study

Charles Béguelin¹, Nicole Friolet¹, Darius Moradpour², Roland Sahli³, Franziska Suter-Riniker⁴, Alexander Lüthi⁴, Matthias Cavassini⁵, Huldrych F. Günthard^{6,7}, Manuel Battegay⁸, Enos Bernasconi⁹, Patrick Schmid¹⁰, Alexandra Calmy¹¹, Andrew Atkinson¹, Andri Rauch¹, Gilles Wandeler^{1,12} and the Swiss HIV Cohort Study

¹Department of Infectious Diseases, Bern University Hospital, University of Bern, Switzerland, ²Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, ³Institute of Microbiology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, ⁴Institute for Infectious Diseases, Faculty of Medicine, University of Bern, Switzerland, ⁵Division of Infectious Diseases, University Hospital Lausanne, University of Lausanne, ⁶Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, ⁷Institute of Medical Virology, University of Zurich, Zurich, ⁸Department of Infectious Diseases & Hospital Hygiene, University Hospital Basel, ⁹Division of Infectious Diseases, Regional Hospital Lugano, ¹⁰Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital St.Gallen, ¹¹Division of Infectious Diseases, University Hospital Geneva, University of Geneva, ¹²Institute of Social and Preventive Medicine, University of Bern

Corresponding Author:

Charles Béguelin, M.D.

Department of Infectious Diseases, Inselspital

Poliklinik Trakt 2B

CH-3010 Bern

Switzerland

E-Mail: charles.beguelin@insel.ch

Tel: +41 31 632 21 11

Abstract

We analyzed changes in hepatitis B virus (HBV) and hepatitis delta virus (HDV) viral loads during tenofovir-containing antiretroviral therapy among patients with a replicating HDV infection in the Swiss HIV Cohort Study. Only 28.6% experienced a ≥ 2.0 log reduction in HDV RNA and 14.3% had undetectable HDV viral load within five years.

Keywords: coinfection, hepatitis delta virus, human immunodeficiency virus, replication, tenofovir

Introduction

In HIV infected patients, hepatitis delta virus (HDV) coinfection is associated with a higher incidence of hepatic flares and decompensation, an increased incidence of hepatocellular carcinoma (HCC), as well as higher mortality(1-3). In the Swiss HIV Cohort Study (SHCS), HDV-infected patients were eight times more likely to die from liver-related complications than HDV-uninfected ones(4). Currently, pegylated interferon (IFN) alpha remains the mainstay of HDV therapy, despite its limited success(5-7). The addition of nucleos(t)ide reverse transcriptase inhibitors (NRTIs) to IFN did not improve virological outcomes in large trials(8-10). The impact of long-term treatment with NRTIs on HDV suppression in HIV/hepatitis B virus (HBV)-coinfected patients has been a matter of debate. While Soriano *et al.* showed a reduction in HDV replication and liver stiffness after a median of 4.8 years of TDF-containing antiretroviral therapy (ART) in HIV/HBV-coinfected individuals in Spain(11), Boyd *et al.* failed to show a similar impact of TDF in a French cohort(12). As TDF is now available as a component of first-line ART throughout the world, more data are needed on its impact on long-term virological outcomes. We assessed the impact of long-term TDF therapy on HBV and HDV replication in a nationwide HIV cohort.

Patients and methods

All SHCS (www.shcs.ch) participants with a positive HBsAg test between January 1988 and December 2014 were considered(13). HDV serology was assessed in all patients as described before(4). For this analysis, we included all patients with an HDV RNA >300 cp/ml at TDF initiation and who had a follow-up sample after at least one year of TDF. All routine data were collected prospectively within the framework of the SHCS. Local Ethical Committees of all participating study sites have approved the study and written consent has been obtained from all participants.

For HDV amplification, total nucleic acids were purified from 200 μ l plasma (Qiagen EZ1 DSP kit), and cDNA (High Capacity cDNA Reverse Transcription Kit, Applied BiosystemsTM)

was subjected to real-time polymerase chain reaction (PCR) according to Ferns et al(14). HDV genotype was assessed by sequencing and phylogenetic analysis of a 260-base-pair cDNA fragment encompassing the 3' end of the hepatitis D antigen coding region. HBV DNA was quantified using the COBAS AmpliPrep/TaqMan48 system (Roche Diagnostics International AG, Switzerland). HBV genotyping was performed by PCR Amplification, Sanger sequencing and subsequent *in silico* analysis by the geno2pheno tool (<http://hbv.geno2pheno.org/index.php>) as described previously(15). HBV suppression was defined as HBV DNA <20 IU/ml and low-level viremia as HBV DNA 20-2000 IU/ml. Quantitative HBsAg (qHBsAg) was analyzed with a fully automated chemiluminescent microparticle immunoassay (Architect, Abbott Diagnostics, USA).

Demographic and clinical characteristics at TDF start were described using absolute numbers and proportions, or medians and interquartile ranges (IQR). Individual follow-up started at initiation of TDF and ended on the date of death, loss to follow-up, TDF interruption or database closure (31.12.2014), whichever happened first. The proportion of patients reaching HDV RNA suppression or experiencing a viral load drop ≥ 2 log were described and their main characteristics compared with those of the other patients using Fisher's exact and Mann-Whitney tests. Changes in HBV DNA and qHBsAg levels were also described. Statistical analyses were performed using Stata Version 13.1.

Results

Study population

Of 73 patients with replicating HDV in the SHCS, 34 (46%) had been on TDF for more than a year and follow-up samples were available in 21 of them. At baseline, patients were predominantly middle-aged (median: 40 years [IQR 35-45]) males (19/21 [90.5%]) from north-western Europe (15/21 [71.4%]). Only 2/21 (9.5%) patients were from sub-Saharan Africa ([Supplementary Table](#)). Thirteen of the 21 (61.9%) were persons who currently or previously injected drugs (PWID). Most individuals had already been on another ART regimen at time of TDF start (80.9%) for a median of 6.3 years and 70.6% of them had a suppressed HIV viral load. Prior lamivudine treatment was present in 8/21 (38.1%) patients. Two thirds had a CD4 count < 350 cells/ μ l. At TDF start, one half of the patients had either suppressed (5/21, 23.8%) or low-level (6/21, 28.6%) HBV DNA. Of 11 patients with available results from HBV sequencing, 8 were infected with genotype D and 3 with genotype A. All patients were infected with HDV genotype 1. Median qHBsAg was 3.9 log₁₀ IU/ml (IQR 3.4-4.1). Two-thirds had a positive anti-HCV serology (66.7%) whereas only 2/21 (9.5%) patients had detectable HCV RNA. Transaminases were elevated [ACTG (AIDS Clinical Trials Group) grade 1-4] in 15/21 (75%) of the patients.

HBV and HDV follow-up parameters

Patients were followed for a median of 4.9 years (IQR 2.4-7.7) on TDF. Two of the 21 patients died during follow-up, one from HCC and one from decompensated cirrhosis, and no patients were lost to follow-up. Median HDV RNA was 7.0 log₁₀ cp/ml (IQR 5.7-8.1) before TDF initiation and 6.7 log₁₀ cp/ml (IQR 4.6-7.2) at the last follow-up visit ([Figure](#)). Sixteen of the 21 patients (76%) reached HBV suppression (<20 IU/ml) after a median of 2.9 years (IQR 2.0-3.1) and the 5 remaining patients had low-level viremia. qHBsAg was 3.9 log₁₀ IU/ml at TDF initiation and 3.6 log₁₀ IU/ml (IQR 3.1-3.9) at the last follow-up visit. Six (28.6%) patients experienced >2 log₁₀ HDV RNA reduction during follow-up, and HDV RNA became undetectable in three of them (14.3%). No differences in HBV DNA levels, qHBsAg, liver enzymes or HIV-1 related characteristics were noted between individuals with and without HDV RNA reduction during TDF treatment. These six patients were all men, were slightly younger (37 years [IQR 35-40] vs. 43 [IQR 36-46]), had a lower baseline HDV RNA (5.8 [IQR 3.2-7.7] log₁₀ cp/ml vs. 7.3 [IQR 5.9-8.1]) and were less likely to be on an HBV-active treatment at TDF start (1/6 [16.7%] vs. 7/15 [46.7%]), but none of these results were statistically significant. The 3 patients who achieved HDV suppression during follow-up had lower HDV RNA (3.2 [IQR 3.1-5.5] log₁₀ cp/ml vs. 7.4 [IQR 6.0-8.1], p=0.01) and lower qHBsAg (2.1 [IQR -0.7-3.5] log₁₀ cp/ml vs. 4.0 [IQR 3.8-4.1], p=0.02) at baseline and none of them was pre-treated with an HBV-active drug. HBsAg loss was only observed in one patient who initiated TDF with a very low baseline qHBsAg.

Discussion

Among 21 HIV/HBV-coinfected individuals with a replicating HDV infection at TDF initiation, only a minority experienced a reduction of at least 2 log in HDV viral load during a median of 5 years of therapy and only three individuals reached HDV RNA suppression despite successful HBV therapy. In most patients, TDF therapy was not associated with a decrease in HDV RNA levels, which underlines the need for alternative therapies in order to control HDV in this population at high risk of liver-related events.

In line with the results from a cohort of 17 patients in France we found that HDV RNA decreased minimally during TDF treatment, and that only a minority of patients achieved full HDV suppression(12). Our results contrast with the findings from a Spanish cohort in which HDV RNA dropped significantly in all 19 participants after a median time of 54 months(11). The main reasons for these differences across studies cannot be explained by major differences in demographic and HIV-related characteristics. In all three studies, concentrations of HBsAg seemed not to be affected by TDF (11, 12, 16). Despite the limited success of TDF in treating HDV infection, positive outcomes seem to be possible in selected individuals, as reported previously in HIV-uninfected individuals (17, 18). We recently

reported the case of an HIV/HBV/HDV-coinfected patient with an uncontrolled hepatitis delta after initial suppression on TDF (19). In this case, the observation that initial HDV suppression was achieved when the patient had a low CD4 cell count pointed towards a potential role of immunological recovery in the suppression of HDV infection. In the present study, the three patients who achieved HDV suppression did not have a severe impairment of cellular immunity but had lower HDV-RNA and qHBsAg at baseline compared to the other patients. Interestingly, they were not treated with HBV-active drugs before TDF initiation and might have benefitted from the initial impact on HBV infection from this drug. It is uncertain if these patients would have cleared HDV without TDF treatment.

We studied the impact of TDF on HDV replication in a nationwide cohort of HIV/HBV-coinfected individuals. Detailed virological analyses allowed the thorough assessment of the long-term impact of TDF-containing ART on HDV outcomes. Unfortunately we did not have data on liver fibrosis at different time-points for most patients, which limited the robustness of our results regarding clinical outcomes. Furthermore, 13 patients had to be excluded from our analyses because they did not have a stored serum or plasma sample available, or were lost to follow-up.

In conclusion, TDF is highly efficient in suppressing HIV and HBV replication in patients coinfecting with HDV. However, in the majority of these patients TDF did not result in a reduction of HDV RNA or qHBsAg. As replicating HDV infection is strongly associated with liver-related mortality, there is an urgent need for new treatment options.

NOTES:

Acknowledgments

We thank the participating patients, physicians and study nurses for excellent patient care, the data- and the coordination center for continuous support. The members of the SHCS are: Aubert V, Battegay M, Bernasconi E, Böni J, Braun DL, Bucher HC, Calmy A, Cavassini M, Ciuffi A, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H (Chairman of the Clinical and Laboratory Committee), Fux CA, Günthard HF (President of the SHCS), Haerry D (deputy of "Positive Council"), Hasse B, Hirsch HH, Hoffmann M, Hösli I, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kouyos RD, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, Marzolini C, Metzner KJ, Müller N, Nicca D, Pantaleo G, Paioni P, Rauch A (Chairman of the Scientific Board), Rudin C (Chairman of the Mother & Child Substudy), Scherrer AU (Head of Data Centre), Schmid P, Speck R, Stöckle M, Tarr P, Trkola A, Vernazza P, Wandeler G, Weber R, Yerly S.

Financial support

This work was performed within the framework of the SHCS, supported by the Swiss National Science Foundation (SNF grant number 33CSC0-108787, SHCS project number 769). GW was supported by an Ambizione-PROSPER fellowship from the Swiss National Science Foundation (PZ00P3_154730).

DISCLAIMER:

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conflict of interest

The authors who have taken part in this study declared their conflicts of interest using the ICMJE Form for Disclosure of Potential Conflicts of Interest.

References

1. Fernandez-Montero JV, Vispo E, Barreiro P, Sierra-Enguita R, de Mendoza C, Labarga P, et al. Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2014;58(11):1549-53.
2. Sheng WH, Hung CC, Kao JH, Chang SY, Chen MY, Hsieh SM, et al. Impact of hepatitis D virus infection on the long-term outcomes of patients with hepatitis B virus and HIV coinfection in the era of highly active antiretroviral therapy: a matched cohort study. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*. 2007;44(7):988-95.
3. Lee CY, Tsai HC, Lee SS, Wu KS, Sy CL, Chen JK, et al. Higher rate of hepatitis events in patients with human immunodeficiency virus, hepatitis B, and hepatitis D genotype II infection: a cohort study in a medical center in southern Taiwan. *J Microbiol Immunol Infect*. 2015;48(1):20-7.
4. Béguelin C, Moradpour D, Sahli R, Suter-Riniker F, Lüthi A, Cavassini M, Günthard H F, Battegay M, Bernasconi E, Schmid P, Calmy A, Braun D, Furrer H, Rauch A, Wandeler G and the Swiss HIV Cohort Study. Hepatitis delta-associated mortality in HIV/HBV-coinfectd patients. *J Hepatol*. in press.
5. Hadziyannis SJ. Use of alpha-interferon in the treatment of chronic delta hepatitis. *J Hepatol*. 1991;13 Suppl 1:S21-6.
6. Niro GA, Rosina F, Rizzetto M. Treatment of hepatitis D. *J Viral Hepat*. 2005;12(1):2-9.
7. Rizzetto M, Smedile A. Pegylated interferon therapy of chronic hepatitis D: in need of revision. *Hepatology*. 2015;61(4):1109-11.
8. Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. *N Engl J Med*. 2011;364(4):322-31.
9. Yurdaydin C, Bozkaya H, Onder FO, Senturk H, Karaaslan H, Akdogan M, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. *J Viral Hepat*. 2008;15(4):314-21.
10. Wedemeyer H, Yurdaydin C et al. Prolonged therapy of hepatitis delta for 96 weeks with PEG-IFNa-2a plus tenofovir or placebo does not prevent HDV RNA relapse: The HIDIT-2 Study. *EASL-ILC 2014*.
11. Soriano V, Vispo E, Sierra-Enguita R, Mendoza C, Fernandez-Montero JV, Labarga P, et al. Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients. *Aids*. 2014;28(16):2389-94.
12. Boyd A, Mialhes P, Brichler S, Scholtes C, Maylin S, Delaugerre C, et al. Effect of tenofovir with and without interferon on hepatitis D virus replication in HIV-hepatitis B virus-hepatitis D virus-infected patients. *AIDS Res Hum Retroviruses*. 2013;29(12):1535-40.
13. Swiss HIVCS, Schoeni-Affolter F, Ledergerber B, Rickenbach M, Rudin C, Gunthard HF, et al. Cohort profile: the Swiss HIV Cohort study. *Int J Epidemiol*. 2010;39(5):1179-89.
14. Ferns RB, Nastouli E, Garson JA. Quantitation of hepatitis delta virus using a single-step internally controlled real-time RT-qPCR and a full-length genomic RNA calibration standard. *J Virol Methods*. 2012;179(1):189-94.
15. Hirzel C, Wandeler G, Owczarek M, Gorgievski-Hrisoho M, Dufour JF, Semmo N, et al. Molecular epidemiology of hepatitis B virus infection in Switzerland: a retrospective cohort study. *BMC Infect Dis*. 2015;15:483.
16. Maylin S, Boyd A, Lavocat F, Gozlan J, Lascoux-Combe C, Mialhes P, et al. Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients. *Aids*. 2012;26(8):939-49.
17. Babiker ZO, Hogan C, Ustianowski A, Wilkins E. Does interferon-sparing tenofovir disoproxil fumarate-based therapy have a role in the management of severe acute hepatitis delta superinfection? *J Med Microbiol*. 2012;61(Pt 12):1780-3.
18. James G, Sidhu P, Raza M. First report of successful clearance of hepatitis B and D coinfection with tenofovir monotherapy. *Hepatology*. 2015;62(1):317-8.

19. Beguelin C, Vazquez M, Moradpour D, Sahli R, Suter F, Rauch A, et al. Uncontrolled hepatitis delta virus infection after initial suppression on tenofovir in a HIV/HBV-coinfected patient. *Aids*. 2016;30(3):530-3.

Figure:

Hepatitis D virus (HDV) RNA, Hepatitis B virus (HBV) DNA, quantitative Hepatitis B surface antigen (HBsAg) and alanine aminotransferase (ALT) trajectories during tenofovir (TDF)-containing ART

